niftify.in

Mint

Stock market today: Birlasoft, Granules, RBL Bank among ten stocks in F&O ban list on Sept 19

Aarti Industries, Balrampur Chini, Biocon, Birlasoft, GNFC, Granules India, LIC Housing Finance, Oracle Financial Services, PNB, and RBL Bank are the ten stocks on the NSE's F&O ban list on September 19.

Mint

Stock market today: Biocon, GNFC, PNB among ten stocks in F&O ban list on Sept 18

Aarti Industries, Balrampur Chini, Biocon, Birlasoft, GNFC, Granules India, Hindustan Copper, LIC Housing, PNB, and RBL Bank are the ten stocks on the NSE's F&O ban list on Sept 18

CNBC TV18

LIC raises its stake in Biocon from 4.982% to 5.023%

Under the updated disclosure regulations, LIC's ownership has risen from 5,98,14,429 shares to 6,03,14,429 shares.

The Economic Times

Biocon Biologics is planning to raise $950 million through overseas bonds

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from acquiring Viatris Inc.'s biosimilars business. The company has already prepaid $250 million and is exploring ways to reduce finance costs. The bond's rating will determine its pricing.

Business Standard

Need innovation-driven value creation in biotech: Kiran Mazumdar-Shaw

Biocon Chairperson Kiran Mazumdar-Shaw on Thursday called for more investment in research and development to drive innovation and foster culture of intellectual property. She highlighted how the country, already the world's largest exporter of generics and a major player in vaccine production, can achieve greater value by nurturing innovation. Mazumdar-Shaw called for a shift in focus toward value creation through innovation. "India ranks 14th in terms of value in the global pharma landscape. We need to invest in R&D and foster a culture of intellectual property to capture greater value," she said. Addressing a session during the Global Bio-India 2024 event, she positioned the country as a future global leader in biosciences and innovation. Mazumdar-Shaw emphasized India's unique advantages in becoming a global bio-innovation hub, citing the nation's rich scientific talent, robust technological capabilities, and entrepreneurial drive. "Biology is not only the most exciting and ...

The Economic Times

Kiran Mazumdar-Shaw calls for innovation-driven value creation in India's biotech sector

Biocon Chairperson Kiran Mazumdar-Shaw urges increased investment in research and development to drive innovation and intellectual property culture. Speaking at Global Bio-India 2024, she highlights India's potential as a global bio-innovation hub, emphasizing its scientific talent and technological capabilities. She also underscores the importance of biotechnology in healthcare and agriculture.

CNBC TV18

'I’ve built this business to last, not for sale', says Biocon's Kiran Mazumdar-Shaw on sellout rumours

Kiran Mazumdar-Shaw has reaffirmed that Biocon is not for sale, despite market rumours. The company is focusing on reducing debt, expanding into biosimilars, and capitalising on global opportunities, including the US Bio Secure Act.

Mint

Stock market today: Bandhan Bank, Biocon, RBL Bank among seven stocks in F&O ban list on Sept 9

Aditya Birla Fashion, Balrampur Chini Mills, Bandhan Bank, Biocon, Chambal Fertilisers, Hindustan Copper and RBL Bank are the seven stocks on the NSE's F&O ban list on Sept 9

The Economic Times

F&O Ban List: Biocon, RBL Bank among 7 stocks under trade ban on Friday

Seven stocks, including Aditya Birla Fashion and Retail, Balrampur Chini, and Bandhan Bank, are under an F&O trade ban as their open interest crossed 95% of market-wide positions limits. The ban is lifted only if the open interest falls below 80%. Sensex and Nifty50 closed lower due to global market weakness.

Business Line

Stock to buy today: Biocon (₹379.30): BUY

Biocon share price can rise to ₹400

CNBC TV18

Abbott India, Cipla, Biocon may get some relief from the GST Council: Exclusive

Sources further said that the GST council nominated fitment committee is likely to reduce GST on cancer drugs like Trastuzumab Deruxtecan, Osimertinib, Durvalumab to 5% from the current levels of 12%.

Business Standard

Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure

Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure. Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The medicine is also used to treat paediatric patients over the age of one year. The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.

The Economic Times

Biocon unit gets USFDA nod for generic drug

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.

CNBC TV18

Biocon arm Biocon Pharma receives US FDA approval for Daptomycin injection

Shares of Biocon Ltd ended at ₹359.30, up by ₹4.05, or 1.14% on the BSE.

CNBC TV18

Biocon receives FDA report, can start supplies to US from Vizag facility

With this approval, Biocon is authorised to begin commercial supplies from this greenfield active pharmaceutical ingredient (API) facility to the US market. Shares of Biocon Ltd ended at ₹359.30, up by ₹4.05, or 1.14%, on the BSE.

CNBC TV18

Biocon Biologics signs settlement agreement with Janssen to launch Biosimilar Bmab 1200 in multiple countries

Biocon Biologics Share Price | Stelara (Ustekinumab) is a monoclonal antibody medication that targets interleukin IL-12/23, which is involved in immune responses related to conditions such as psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

The Economic Times

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson to launch Bmab 1200, a biosimilar to Stelara, in Europe, the UK, Canada, and Japan. This deal resolves patent disputes and secures future market entry, pending regulatory approvals.

Business Line

Biocon Biologics clears path for Stelara Biosimilar in major markets

Biocon Biologics CEO Shreehas Tambe says Bmab 1200 will strengthen its immunology franchise, enabling it to offer an affordable and effective treatment option for patients impacted by autoimmune diseases

The Economic Times

Biocon arm's growth formula: US rollouts & debt reduction

Biocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emphasized debt reduction and cost optimization, having paid $175 million out of $335 million for a key acquisition. Their revenue increased 3% in Q1FY25 due to gains in the biosimilars market.

Business Line

Biocon’s Syngene expected to turn headwinds into tailwinds by the second half

However, Biocon’s other two business segments including contract research services and generics saw some challenges

Business Line

Biocon Limited reports 30% y-o-y rise in consolidated revenues in Q1 FY25

Biocon Limited reports 30% revenue growth in Q1FY25, driven by strong performance in Biosimilars and Generics businesses

The Economic Times

Vedanta, Biocon among 5 stocks with short buildup

A short buildup occurs when there is an increase in open interest and trading volumes alongside a decline in the price of the underlying stock in the Futures and Options segment.

Mint

Nifty 50 July series: From Vedanta to Biocon—4 stocks where investors can park their money; Do you own?

Vedanta, Biocon, United Breweries Ltd (UBL), and Indus Tower are the top picks for the June series, according to Religare Broking. Here's why the brokerage sees the stocks outperforming this month.

Mint

Latest Market News Today Live Updates June 30, 2024: Nifty 50 July series: From Vedanta to Biocon—4 stocks where investors can park their money; Do you own?

Latest Market News Today Live Updates: Follow Mint's market blog for real-time updates on your favourite companies. This blog keeps you informed on all things Dalal Street and global markets.

Business Line

Biocon Biologics receives approval from EMA to manufacture biosimilar Bevacizumab

This approval will provide significant additional capacity to address patients’ needs across markets in Europe

The Economic Times

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patients' needs in Europe for treating cancer. The Bengaluru facility was also approved for biosimilar Trastuzumab manufacturing. EMA renewed GMP certificates for Biocon's facilities in Bengaluru and Malaysia. USFDA issued four observations after inspecting Biocon's Andhra Pradesh plant, concluding inspections on June 21, 2024.

The Economic Times

Biocon gets 4 observations from USFDA for Andhra Pradesh facility

Biocon received four observations from the US health regulator after a GMP inspection at its API facility in Andhra Pradesh.

The Economic Times

Biocon seeks partner to test generic Wegovy, Ozempic in China

India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find a partner for the trials on over 500 patients in China, citing the substantial investment required. The move comes ahead of the patent protection expiry on key ingredients in the drugs in 2026.